Validity of the German Version of the FCR-1r Questionnaire in Patients with Urologic Cancer.

IF 1.4 4区 医学 Q3 ONCOLOGY
Can Dümdüz, Sebastian Sage, Sofia Kugler, Günter Niegisch, Christian Schulz-Quach, Ralf Schäfer, André Karger, Ulrike Dinger, Dominik Fugmann
{"title":"Validity of the German Version of the FCR-1r Questionnaire in Patients with Urologic Cancer.","authors":"Can Dümdüz, Sebastian Sage, Sofia Kugler, Günter Niegisch, Christian Schulz-Quach, Ralf Schäfer, André Karger, Ulrike Dinger, Dominik Fugmann","doi":"10.1159/ort/aecag002","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Fear of cancer recurrence (FCR) is a prevalent and distressing issue for a significant proportion of cancer patients across various disciplines, yet it remains one of the most frequently unaddressed psychosocial needs. A key barrier to identifying affected individuals is the lack of brief screening tools suitable for clinical settings. The objective of this research is to validate the one-item FCR screening tool (revised Fear of Cancer Recurrence-1 [FCR-1r]) in a German cohort of urologic cancer patients. Validating such an ultra-brief measure may help address this clinically relevant gap and serve as a viable, clinically applicable alternative to lengthy questionnaires.</p><p><strong>Methods: </strong>Statistical analyses were conducted using R software. Criterion validity was assessed against the Concerns About Recurrence Questionnaire-4 (CARQ-4). Convergent validity was tested against the Fear of Progression Questionnaire - Short Form (FoP-Q-SF) and Generalised Anxiety Disorder-7 (GAD-7). Discriminant validity was tested against the Health Literacy Survey-European-Questionnaire 16 (HLS-EU-Q16). Validity was assessed using chi-square tests with phi coefficients, accuracy measures, negative and positive predictive values, sensitivity, specificity and odds ratios.</p><p><strong>Results: </strong>The final analysis sample consisted of 236 participants with complete data on all study measures. The FCR-1r demonstrated excellent criterion validity with respect to the CARQ-4 (χ2[1] = 101.97, p < 0.001, φ = 0.66), with an overall accuracy of 84% (95% CI: 79-89%). Sensitivity was 84%, and specificity was 85%. The analysis of convergent validity revealed a moderate association with both the FoP-Q-SF (χ2[1] = 20.25, p < 0.001, φ = 0.29; accuracy 62% [95% CI: 56-68%]) and the GAD-7 (χ2[1] = 11.82, p < 0.001, φ = 0.22; accuracy 64% [95% CI: 58-70%]). The analysis of discriminant validity showed no significant association between the FCR-1r and health literacy (HLS-EU-Q16): χ2(1) = 3.44, p = 0.064, φ = 0.12.</p><p><strong>Conclusion: </strong>The German version of the FCR-1r demonstrates good psychometric properties, confirming its validity as a tool for assessing FCR in clinical practice.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"1"},"PeriodicalIF":1.4000,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688376/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/ort/aecag002","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Fear of cancer recurrence (FCR) is a prevalent and distressing issue for a significant proportion of cancer patients across various disciplines, yet it remains one of the most frequently unaddressed psychosocial needs. A key barrier to identifying affected individuals is the lack of brief screening tools suitable for clinical settings. The objective of this research is to validate the one-item FCR screening tool (revised Fear of Cancer Recurrence-1 [FCR-1r]) in a German cohort of urologic cancer patients. Validating such an ultra-brief measure may help address this clinically relevant gap and serve as a viable, clinically applicable alternative to lengthy questionnaires.

Methods: Statistical analyses were conducted using R software. Criterion validity was assessed against the Concerns About Recurrence Questionnaire-4 (CARQ-4). Convergent validity was tested against the Fear of Progression Questionnaire - Short Form (FoP-Q-SF) and Generalised Anxiety Disorder-7 (GAD-7). Discriminant validity was tested against the Health Literacy Survey-European-Questionnaire 16 (HLS-EU-Q16). Validity was assessed using chi-square tests with phi coefficients, accuracy measures, negative and positive predictive values, sensitivity, specificity and odds ratios.

Results: The final analysis sample consisted of 236 participants with complete data on all study measures. The FCR-1r demonstrated excellent criterion validity with respect to the CARQ-4 (χ2[1] = 101.97, p < 0.001, φ = 0.66), with an overall accuracy of 84% (95% CI: 79-89%). Sensitivity was 84%, and specificity was 85%. The analysis of convergent validity revealed a moderate association with both the FoP-Q-SF (χ2[1] = 20.25, p < 0.001, φ = 0.29; accuracy 62% [95% CI: 56-68%]) and the GAD-7 (χ2[1] = 11.82, p < 0.001, φ = 0.22; accuracy 64% [95% CI: 58-70%]). The analysis of discriminant validity showed no significant association between the FCR-1r and health literacy (HLS-EU-Q16): χ2(1) = 3.44, p = 0.064, φ = 0.12.

Conclusion: The German version of the FCR-1r demonstrates good psychometric properties, confirming its validity as a tool for assessing FCR in clinical practice.

德国版FCR-1r问卷在泌尿系统癌患者中的有效性。
癌症复发恐惧(Fear of Cancer Recurrence, FCR)是各学科中相当大比例的癌症患者普遍存在且令人痛苦的问题,但它仍然是最常未得到解决的心理社会需求之一。识别受影响个体的一个关键障碍是缺乏适合临床环境的简短筛查工具。本研究的目的是在德国泌尿系统癌症患者队列中验证一项FCR筛查工具(FCR-1r)。验证这种超简短的措施可能有助于解决这一临床相关差距,并作为一种可行的,临床适用的替代冗长的问卷调查。方法采用R软件进行统计学分析。根据CARQ-4评估标准效度。对FoP-Q-SF和GAD-7进行收敛效度检验。采用HLS-EU-Q16进行判别效度检验。使用卡方检验评估有效性,包括phi系数、准确性测量、阴性和阳性预测值、敏感性、特异性和优势比。结果最终分析样本包括236名参与者,所有研究措施的数据完整。FCR-1r相对于CARQ-4表现出极好的标准效度(χ²(1)= 101.97,p < 0.001, φ = 0.66),总体准确性为84% (95% CI: 79-89%)。敏感性为84%,特异性为85%。收敛效度分析显示,与FoP-Q-SF (χ²(1)= 20.25,p < 0.001, φ = 0.29;准确性62% (95% CI: 56-68%)和广泛性焦虑障碍-7 (GAD-7) (χ²(1)= 11.82,p < 0.001, φ = 0.22;准确率64% (95% CI: 58-70%))。判别效度分析显示,FCR-1r与健康素养(HLS-EU-Q16)无显著相关:χ 2 (1) = 3.44, p = 0.064, φ = 0.12。结论德文版本的FCR-1r具有良好的心理测量特性,在临床实践中证实了其作为评估癌症复发恐惧的有效工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.20
自引率
0.00%
发文量
84
期刊介绍: With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书